Avantor sets Oct. 14 exit date for EVP Gourdier
Avantor, Inc. (AVTR) filed an amended current report to update details about the previously announced transition and planned departure of Benoit Gourdier, Executive Vice President, Bioscience and Medtech Products.
Rhea-AI Filing Summary
Avantor, Inc. (AVTR) filed an amended current report to update details about the previously announced transition and planned departure of Benoit Gourdier, Executive Vice President, Bioscience and Medtech Products. Avantor, through its subsidiary VWR International, LLC, and Mr. Gourdier entered into a Transition Agreement on August 21, 2026, under which he will remain employed through October 14, 2026, when his employment will end. If he remains employed and complies with the Transition Agreement through that date, he will receive severance benefits materially consistent with the company’s Executive Severance and Change in Control Plan, as described in Avantor’s March 27, 2026 proxy statement.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Transition Agreement date: August 21, 2026
Employment end date: October 14, 2026
Proxy statement reference date: March 27, 2026
+1 more
4 metrics
Transition Agreement date
August 21, 2026
Date Avantor, VWR International, LLC and Benoit Gourdier agreed to the Transition Agreement
Employment end date
October 14, 2026
Date on which Benoit Gourdier’s employment with Avantor will end if he remains under the Transition Agreement
Proxy statement reference date
March 27, 2026
Date of Avantor’s proxy statement describing the Executive Severance and Change in Control Plan
Amendment signature date
August 27, 2026
Date the report was signed on behalf of Avantor, Inc.
Key Terms
Transition Agreement, Executive Severance and Change in Control Plan, Inline XBRL
3 terms
Transition Agreement financial
"agreed to a transition arrangement (the “Transition Agreement”), pursuant to which"
Executive Severance and Change in Control Plan financial
"benefits materially consistent with the terms of the Company’s Executive Severance and Change in Control Plan"
Inline XBRL technical
"The cover page from this on /A, formatted in Inline XBRL"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
FAQ
What does Avantor, Inc. (AVTR) disclose in this 8-K/A amendment?
Avantor, Inc. provides the confirmed departure date and transition terms for Executive Vice President Benoit Gourdier. It states that under a Transition Agreement, he will remain employed through October 14, 2026, after which his employment will end, with potential severance benefits if conditions are met.
When will Avantor executive Benoit Gourdier leave the company?
Benoit Gourdier will leave Avantor on October 14, 2026. The amendment states he will continue his employment through that date under a Transition Agreement, after which his employment with the company will end.
What is the Transition Agreement mentioned by Avantor (AVTR)?
The Transition Agreement, dated August 21, 2026, provides that Benoit Gourdier will continue his employment through October 14, 2026. If he remains employed and complies with its terms through that date, he will be entitled to severance benefits consistent with Avantor’s Executive Severance and Change in Control Plan.
What severance benefits may Benoit Gourdier receive from Avantor (AVTR)?
If Benoit Gourdier remains employed and complies with the Transition Agreement through October 14, 2026, he will receive severance benefits materially consistent with Avantor’s Executive Severance and Change in Control Plan, as described in the company’s March 27, 2026 proxy statement.
Why did Avantor (AVTR) file this Form 8-K/A amendment?
Avantor filed this 8-K/A because the original 8-K about Benoit Gourdier’s role change and planned departure did not include a specific departure date. The amendment supplies that date and outlines the related Transition Agreement terms.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 17, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐ Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 23, 2026, Avantor, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) disclosing that Benoit Gourdier, the Company’s Executive Vice President, Bioscience and Medtech Products, would transition to a new role supporting the Company’s segment integration activities for a period of time, after which he would depart the Company. The Original 8-K did not include Mr. Gourdier’s departure date because, at the time, his departure date had not been determined. This Form 8-K/A is being filed for the purpose of providing Mr. Gourdier’s departure date.
On August 21, 2026, the Company, through its subsidiary VWR International, LLC, and Mr. Gourdier agreed to a transition arrangement (the “Transition Agreement”), pursuant to which Mr. Gourdier will continue his employment with the Company through October 14, 2026, after which his employment will end. If Mr. Gourdier remains employed and complies with the terms of the Transition Agreement until October 14, 2026, he will be entitled to receive severance benefits materially consistent with the terms of the Company’s Executive Severance and Change in Control Plan, which are described in the Company’s proxy statement filed with the Securities and Exchange Commission on March 27, 2026.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |||||||
| 104 | The cover page from this Current Report on Form 8-K/A, formatted in Inline XBRL | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Avantor, Inc. | |||||||||||
| Date: August 27, 2026 | By: | /s/ Claudius Sokenu | |||||||||
| Name: | Claudius Sokenu | ||||||||||
| Title: | Executive Vice President, Chief Legal and Compliance Officer and Secretary (Duly Authorized Officer) | ||||||||||